| CAS NO: | 150399-21-6 |
| 包装 | 价格(元) |
| 250mg | 电议 |
| 500mg | 电议 |
| Cas No. | 150399-21-6 |
| 别名 | 巴柳氮钠水合物; Balsalazide disodium dihydrate |
| Canonical SMILES | [O-]C(CCNC(C1=CC=C(/N=N/C2=CC=C([O-])C(C(O)=O)=C2)C=C1)=O)=O.[Na+].[Na+].O.O |
| 分子式 | C17H17N3Na2O8 |
| 分子量 | 437.31 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Balsalazide sodium hydrate could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway. STAT3 IL-6 At the endpoint, the protein production of MIP-1β, MCP-1, IL-6, and IL-10 in the colon tissues decrease in concordance with the plasma concentrations of the cytokines. The drug-treated groups reveal lower expression of p-STAT3 compared to the CAC group. In addition, BCL2 decreases and BAX increases markedly in the BSZ+VSL#3 group[1]. Balsalazide is a new 5-aminosalicylic acid (5-ASA) containing prodrug[2]. [1]. Do EJ, et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016 Aug;31(8):1453-61. [2]. Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut, 2001. 49(6): p. 783-789. |
m.cnreagent.com